Phage therapy program
GangaGen Biotechnologies
| Status | Research/development |
|---|---|
| Type | Company |
| Location | Bengaluru; India |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Official company pages describe R&D and collaboration; info@gangagen.com is a corporate contact. Human antibacterial pipeline emphasizes protein-based products. No current whole-phage patient access verified. |
|---|---|
| Areas of work | Human phage-derived protein/lysin antibacterials including P128; company states whole-bacteriophage applications shifted to nonhuman food, veterinary, environmental and agriculture markets in 2007. |
| International access | Not stated in checked sources; do not infer eligibility from international collaborations. |
What to confirm
- Phage-derived lysins and living phage therapy are different modalities.
- GangaGen is not Ganga Hospital, and neither a company name nor the Ganga river establishes hospital access.
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | in-gangagen |
|---|